{"id":"ctss","name":"CTSS","symbol":"CTSS","route":"/targets/ctss/","asOf":"2026-09-23","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2545","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163131","uniprot":"https://www.uniprot.org/uniprotkb/P25774/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P25774","open-targets":"https://platform.opentargets.org/target/ENSG00000163131","civic":"https://civicdb.org/genes/1520/summary","oncokb":"https://www.oncokb.org/gene/CTSS","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CTSS","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CTSS","depmap":"https://depmap.org/portal/gene/CTSS?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000163131-CTSS","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1520","omim":"https://www.omim.org/entry/116845"}],"products":[{"id":"abenacianine","name":"Abenacianine","status":"phase-3","modality":"Tumour-targeted fluorescent imaging agent (quenched activity-based probe)","route":"/drugs/abenacianine/"}],"trials":[{"id":"nct05400226","name":"Phase 2 Study of VGT-309 in Lung Cancer","nct":"NCT05400226","phase":"2","status":"completed"},{"id":"nct06145048","name":"Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.","nct":"NCT06145048","phase":"2","status":"completed"},{"id":"nct06034197","name":"Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy","nct":"NCT06034197","phase":"1","status":"historic"}],"pathways":[],"companies":["vergent-bioscience"],"keyPapers":[],"hotspots":[],"openQuestions":[],"assays":[],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}